TransCode Therapeutics, Inc.
As of Oct 22, 2026, TransCode Therapeutics is in Stage 4, the downtrend phase, now in week 27 (since Apr 14, 2026). It closed at $1.72, 87.2% below its 52-week high and below its 200-day average, which is falling.
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is RNAZ early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
RNAZ among Biotechnology504th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …504 | RNAZ | Stage 4 · wk 27 | 8 | +2.1% |
TransCode Therapeutics: quick answers
What stage is TransCode Therapeutics in?
As of Oct 22, 2026, TransCode Therapeutics (RNAZ) is in Stage 4, the downtrend phase. It entered Stage 4 on Apr 14, 2026 and is in week 27. What the four stages mean
Is TransCode Therapeutics in an uptrend?
No. TransCode Therapeutics is in a Stage 4 downtrend. It trades 73.0% below its 200-day average, which is falling.
How far is TransCode Therapeutics from its 52-week high?
TransCode Therapeutics closed at $1.72 on Oct 22, 2026, 87.2% below its 52-week high of $13.39. Its 52-week low is $1.55.
How has TransCode Therapeutics performed over the past year?
As of Oct 22, 2026, TransCode Therapeutics is down 87.5% over the past year and down 76.8% so far in 2026.
Which sector and industry is TransCode Therapeutics in?
TransCode Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor. The company is also developing oncolytic virus therapy. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.